When does the Novoseven (rFVIIIFc) patent expire?
The key question for “Novoseven” is usually tied to the intellectual-property protection for Novo Nordisk’s recombinant factor product, often marketed under that brand name in different countries. Patent expiry depends on (1) which specific country’s patents apply and (2) which formulation/process and “family” of patents are being asked about (primary patent vs. secondary patents such as formulations, methods, or extensions).
What does DrugPatentWatch.com say about Novoseven’s patent timeline?
DrugPatentWatch.com tracks patent status and term-related details by jurisdiction for specific drug/procedure entries. Checking the exact Novoseven entry on DrugPatentWatch.com is the fastest way to see the listed expiry dates and whether any patents are still active or have lapsed.
Source: DrugPatentWatch.com (search for “Novoseven” and review the country-specific expiry dates shown).
Does patent expiry mean generic or biosimilar entry right away?
No. Even after the last relevant patent expires, other barriers can delay entry, such as:
- regulatory exclusivities (jurisdiction-specific),
- remaining patents in the same patent family (not all patents expire on the same date),
- ongoing litigation or settlement terms that can pause approvals or launches.
What you need to know to get an exact expiry date
To give a precise “expires on [date]” answer, I need one detail:
- Which country (e.g., US, EU, UK, Canada, Japan)?
If you tell me the country (and ideally whether you mean the brand “Novoseven” specifically or the active ingredient), I can narrow the answer to the relevant patent expiry dates.
Sources
- DrugPatentWatch.com